Our SILSOL® silica active ingredient delivery technology combines Grace’s extensive expertise in mesoporous silica gel, novel application methods, and patented technologies to accelerate the screening and development of solubility-enhancing solid dispersions, with the added benefit of doing so with compendial, scalable, and available silicas.

The patented technology offers several benefits, including:

  • Enhanced bioavailability through delivery of the amorphous form of active ingredients
  • Sustained stability from amorphous solid dispersions that prevent crystallization/re-crystallization
  • Pharmacopoeia acceptance of our cGMP manufactured silica that conforms to global monographs
  • Scalable cGMP excipient manufacturing from tons to quantities
  • EU Commission Regulation No. 231/2012 (E 551 materials listed on the FDA inactive ingredient database (IID))